$1.15 Billion in Sales Expected for Syneos Health Inc (NASDAQ:SYNH) This Quarter

Wall Street brokerages expect that Syneos Health Inc (NASDAQ:SYNH) will post sales of $1.15 billion for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Syneos Health’s earnings, with the highest sales estimate coming in at $1.16 billion and the lowest estimate coming in at $1.14 billion. Syneos Health posted sales of $1.07 billion during the same quarter last year, which would suggest a positive year over year growth rate of 7.5%. The business is scheduled to report its next quarterly earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Syneos Health will report full year sales of $4.68 billion for the current year, with estimates ranging from $4.66 billion to $4.70 billion. For the next financial year, analysts expect that the business will report sales of $4.98 billion, with estimates ranging from $4.93 billion to $5.05 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Syneos Health.

Syneos Health (NASDAQ:SYNH) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.08. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Syneos Health had a return on equity of 9.55% and a net margin of 0.42%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.55 earnings per share.

Several research analysts have weighed in on SYNH shares. Zacks Investment Research upgraded Syneos Health from a “sell” rating to a “hold” rating in a report on Friday, May 24th. William Blair reiterated an “outperform” rating on shares of Syneos Health in a report on Tuesday, March 19th. Wolfe Research started coverage on Syneos Health in a report on Tuesday, April 2nd. They set a “market perform” rating on the stock. ValuEngine upgraded Syneos Health from a “hold” rating to a “buy” rating in a report on Saturday, March 30th. Finally, Credit Suisse Group lifted their target price on Syneos Health from $49.00 to $51.00 and gave the stock an “outperform” rating in a report on Tuesday, March 19th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $53.33.

SYNH stock opened at $47.12 on Friday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.02 and a current ratio of 1.02. The stock has a market cap of $4.77 billion, a price-to-earnings ratio of 17.98, a price-to-earnings-growth ratio of 1.64 and a beta of 1.41. Syneos Health has a 1-year low of $36.26 and a 1-year high of $56.34.

Institutional investors have recently modified their holdings of the company. Loomis Sayles & Co. L P lifted its holdings in shares of Syneos Health by 135.8% in the first quarter. Loomis Sayles & Co. L P now owns 500 shares of the company’s stock valued at $26,000 after purchasing an additional 288 shares in the last quarter. Enlightenment Research LLC bought a new stake in shares of Syneos Health in the fourth quarter valued at about $51,000. NumerixS Investment Technologies Inc bought a new stake in shares of Syneos Health in the fourth quarter valued at about $57,000. Bessemer Group Inc. bought a new stake in shares of Syneos Health in the fourth quarter valued at about $59,000. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Syneos Health in the first quarter valued at about $61,000.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Featured Article: Different Types of Derivatives

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.